Search: id:"swepub:oai:DiVA.org:uu-300957" >
A novel splicing mu...
A novel splicing mutation in the IQSEC2 gene that modulates the phenotype severity in a family with intellectual disability.
- Article/chapterEnglish2016
Publisher, publication year, extent ...
-
2016-01-06
-
Springer Science and Business Media LLC,2016
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-300957
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300957URI
-
https://doi.org/10.1038/ejhg.2015.267DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
The IQSEC2 gene is located on chromosome Xp11.22 and encodes a guanine nucleotide exchange factor for the ADP-ribosylation factor family of small GTPases. This gene is known to have a significant role in cytoskeletal organization, dendritic spine morphology and synaptic organization. Variants in IQSEC2 cause moderate to severe intellectual disability in males and a variable phenotype in females because this gene escapes from X-chromosome inactivation. Here we report on the first splicing variant in IQSEC2 (g.88032_88033del; NG_021296.1) that co-segregates in a family diagnosed with an X-linked form of ID. In a percentage of the cells, the variant activates an intraexonic splice acceptor site that abolishes 26 amino acids from the highly conserved PH domain of IQSEC2 and creates a premature stop codon 36 amino acids later in exon 13. Interestingly, the percentage of aberrant splicing seems to correlate with the severity of the disease in each patient. The impact of this variant in the target tissue is unknown, but we can hypothesize that these differences may be related to the amount of abnormal IQSEC2 transcript. To our knowledge, we are reporting a novel mechanism of IQSEC2 involvement in ID. Variants that affect splicing are related to many genetic diseases and the understanding of their role in disease expands potential opportunities for gene therapy. Modulation of aberrant splicing transcripts can become a potent therapeutic approach for many of these diseases.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Alvarez-Mora, Maria Isabel
(author)
-
Rosell, Jordi
(author)
-
Rodríguez-Revenga, Laia
(author)
-
Karlberg, OlofUppsala universitet,Molekylär medicin,Science for Life Laboratory, SciLifeLab(Swepub:uu)oka21721
(author)
-
Sauer, Sascha
(author)
-
Syvänen, Ann-ChristineUppsala universitet,Molekylär medicin,Science for Life Laboratory, SciLifeLab(Swepub:uu)anncsyva
(author)
-
Mila, Montserrat
(author)
-
Uppsala universitetMolekylär medicin
(creator_code:org_t)
Related titles
-
In:European Journal of Human Genetics: Springer Science and Business Media LLC24:8, s. 1117-11231018-48131476-5438
Internet link
Find in a library
To the university's database